ID   FR-M-170
AC   CVCL_C547
DR   cancercelllines; CVCL_C547
DR   Cosmic; 2163849
DR   ESTDAB; ESTDAB-163
DR   Wikidata; Q54835147
RX   PubMed=23851445;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Unspecified (PubMed=23851445).
ST   Source(s): ESTDAB=ESTDAB-163
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 11,12
ST   D3S1358: 16,18
ST   D5S818: 13
ST   D7S820: 9,12
ST   FGA: 21,22
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 14
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//